inactivated poliomyelitis vaccine
bilhoven biological - poliomyelitis vaccine - vaccine - one human dose of 0.5 ml ipv contains - inacticated poliomyelitis virus type 1-40 d-antigen units; inactivated poliomyelitis vir
poliomyelitis vaccine (inactivated) - 1 dose suspension for injection
polio trivalent bulk - suspension for injection - inactivated poliomyelitis virus type 1, - poliomyelitis trivalent inactivated whole virus
bivalent poliomyelitis vaccine oral solution
serum instititute of india pvt. ltd. 212/2, hadapsar, pune- 411 028, india. - monovalent bulk of poliomyelitis vaccine - oral solution - each dose of 2 drops (0.1 ml) contains polio - poliomyelitis oral bivalent live attenuated
oral bivalent types 1 and 3 poliomyelitis vaccine suspension and effervescent granules for oral
sanofi pasteur s.a. 2, avenue pont pasteur 69007 lyon france - poliomyelitis virus type 1, ls c2ab strain, - suspension and effervescent granules for oral - each 0.1-ml dose (2 drops) contains:poliomyelitis - viral vaccines: poliomyelitis vaccines
adacel polio pertussis vaccine
sanofi-aventis australia pty ltd - poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu; diphtheria toxoid, quantity: 2 iu; pertussis toxoid, quantity: 2.5 microgram; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; poliovirus, quantity: 29 dagu - injection, suspension - excipient ingredients: aluminium phosphate; formaldehyde; polysorbate 80; neomycin; water for injections; phenoxyethanol; streptomycin sulfate; polymyxin b sulfate; glutaral; ethanol - adacel polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation.,children 4-6 years of age should have already received four doses of dtpa and ipv or opv.,adacel polio is not intended for primary immunisation.,adacel polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.,the use of adacel polio should be determined on the basis of official recommendations. for further information, refer to the current immunisation handbook.
diphtheria, tetanus, poliomyelitis vaccine, suspension for injection (vial)
bilthoven biologicals b.v. antonie van leeuwenhoeklaan 9 3721 ma, bilthoven, netherlands - suspension for injection - poliovirus (inactivated) type 3 (saukett strain) 7.5 dagu diphtheria toxoid >5 iu tetanus toxoid >20 iu poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 4 dagu - vaccines
poliomyelitis 2ml*20 d0se vaccine
biomed - polio vaccine - vaccine - 2ml*20 d0se
ipol (poliovirus type 1 antigen (formaldehyde inactivated), poliovirus type 2 antigen (formaldehyde inactivated), and poliovirus
sanofi pasteur inc. - poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - poliovirus type 1 antigen (formaldehyde inactivated) 40 [d'ag'u] in 0.5 ml - ipol vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. (28) it is recommended that all infants (as young as 6 weeks of age), unimmunized children, and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis. (29) following the eradication of poliomyelitis caused by wild poliovirus from the western hemisphere (including north and south america) (30), an ipv-only schedule was recommended to eliminate vapp. (7) all children should receive four doses of ipv at ages 2, 4, 6 to 18 months, and 4 to 6 years. opv is no longer available in the us and is not recommended for routine immunization. (7) previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete immunization with opv are not contraindications to completing the primary series of immunization with ipol vaccine. children of all ages should have their immuni
polprotec pfs vaccine
chiron pan. - polio vaccine - vaccine - enhanced inactivated poliomyelitis vaccine - pfs
inactivated poliomyelitis vaccine suspension for injection
bilthoven biologicals b.v antonie van leeuwenhoeklaan 9-13, bilthoven, 3721 - inactivated poliomyelitis virus type 1 - suspension for injection - inactivated poliomyelitis virus type 1 -40 - viral vaccines: poliomyelitis vaccines